Research analysts at StockNews.com began coverage on shares of Cellectis (NASDAQ:CLLS – Get Free Report) in a research note issued to investors on Wednesday. The firm set a “sell” rating on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback